{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:07:31Z","timestamp":1777363651298,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"DOI":"10.7759\/cureus.107854","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:28:56Z","timestamp":1777361336000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Significance of Her-2\/Neu and Ki-67 Expression in Gallbladder Carcinoma: A Clinicopathological Study Across Resectable and Advanced Stages"],"prefix":"10.7759","author":[{"given":"Neha","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipsita","family":"Dhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagat Singh","family":"Lali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Patne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachariah","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parul","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipinesh","family":"Sansar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla P","year":"2019","unstructured":"Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019, 5:93-102. 10.5114\/ceh.2019.85166","journal-title":"Clin Exp Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1183619","article-title":"Gallbladder cancer: current and future treatment options","volume":"14","author":"Zhou Y","year":"2023","unstructured":"Zhou Y, Yuan K, Yang Y, et al.. Gallbladder cancer: current and future treatment options. Front Pharmacol. 2023, 14:1183619. 10.3389\/fphar.2023.1183619","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000325746","article-title":"HER2 evaluation and its impact on breast cancer treatment decisions","volume":"15","author":"Goddard KA","year":"2012","unstructured":"Goddard KA, Weinmann S, Richert-Boe K, et al.. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics. 2012, 15:1-10. 10.1159\/000325746","journal-title":"Public Health Genomics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: An update","volume":"22","author":"Abrahao-Machado LF","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016, 22:4619-25. 10.3748\/wjg.v22.i19.4619","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092628","article-title":"The role of HER2 status in the biliary tract cancers","volume":"15","author":"Ayasun R","year":"2023","unstructured":"Ayasun R, Ozer M, Sahin I. The role of HER2 status in the biliary tract cancers. Cancers (Basel). 2023, 15:10.3390\/cancers15092628","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174455","article-title":"Ki-67 as a prognostic biomarker in invasive breast cancer","volume":"13","author":"Davey MG","year":"2021","unstructured":"Davey MG, Hynes SO, Kerin MJ, et al.. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021, 13:10.3390\/cancers13174455","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.4103\/jcar.JCar_9_21","article-title":"Expression and clinicopathological correlation of Ki-67 in gallbladder carcinoma","volume":"20","author":"Gupta A","year":"2021","unstructured":"Gupta A, Gupta S, Rajput D, et al.. Expression and clinicopathological correlation of Ki-67 in gallbladder carcinoma. J Carcinog. 2021, 20:11.","journal-title":"J Carcinog"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/13651820410025110","article-title":"Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers","volume":"6","author":"Hidalgo Grau LA","year":"2004","unstructured":"Hidalgo Grau LA, Badia JM, Salvador CA, et al.. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB (Oxford). 2004, 6:174-80. 10.1080\/13651820410025110","journal-title":"HPB (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw206","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"146","author":"Bartley AN","year":"2016","unstructured":"Bartley AN, Washington MK, Ventura CB, et al.. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol. 2016, 146:647-69. 10.1093\/ajcp\/aqw206","journal-title":"Am J Clin Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-024-01723-x","article-title":"Human epidermal growth factor receptor-2\/neu expression in gallbladder cancer is significantly associated with clinicopathological parameters and survival","author":"Dash S","year":"2025","unstructured":"Dash S, Anirvan P, Samantaray S, et al.. Human epidermal growth factor receptor-2\/neu expression in gallbladder cancer is significantly associated with clinicopathological parameters and survival. Indian J Gastroenterol. 2025, 10.1007\/s12664-024-01723-x","journal-title":"Indian J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-018-0162-8","article-title":"Significance of HER2 and Ki-67 in preneoplastic lesions and carcinoma of gallbladder","volume":"50","author":"Halder S","year":"2019","unstructured":"Halder S, Kundu S, Chakraborty J, Chakrabarti S. Significance of HER2 and Ki-67 in preneoplastic lesions and carcinoma of gallbladder. J Gastrointest Cancer. 2019, 50:848-54. 10.1007\/s12029-018-0162-8","journal-title":"J Gastrointest Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.831318","article-title":"HER2 positivity is affected by the papillary structure and has a bidirectional prognostic value for gallbladder carcinoma","volume":"12","author":"Chen L","year":"2021","unstructured":"Chen L, Xu L, Shen L, et al.. HER2 positivity is affected by the papillary structure and has a bidirectional prognostic value for gallbladder carcinoma. Front Genet. 2021, 12:831318. 10.3389\/fgene.2021.831318","journal-title":"Front Genet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal V","year":"2024","unstructured":"Ostwal V, Mandavkar S, Bhargava P, et al.. Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J Clin Oncol. 2024, 42:800-7. 10.1200\/JCO.23.01193","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104655","article-title":"HER2-targeted therapies: unraveling their role in biliary tract cancers","volume":"208","author":"Theocharopoulos C","year":"2025","unstructured":"Theocharopoulos C, Ziogas IA, Mungo B, et al.. HER2-targeted therapies: unraveling their role in biliary tract cancers. Crit Rev Oncol Hematol. 2025, 208:104655. 10.1016\/j.critrevonc.2025.104655","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1898-1","article-title":"A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status","volume":"468","author":"Yoshida H","year":"2016","unstructured":"Yoshida H, Shimada K, Kosuge T, Hiraoka N. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Arch. 2016, 468:431-9. 10.1007\/s00428-015-1898-1","journal-title":"Virchows Arch"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1020","article-title":"Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population","volume":"14","author":"Lago NM","year":"2020","unstructured":"Lago NM, Villar MV, Ponte RV, et al.. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience. 2020, 14:1020. 10.3332\/ecancer.2020.1020","journal-title":"Ecancermedicalscience"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1761440","article-title":"Pattern of care and outcomes of gallbladder cancer patients: retrospective study from a high incidence region in India","volume":"12","author":"Kashyap L","year":"2023","unstructured":"Kashyap L, Singh A, Tomar S, et al.. Pattern of care and outcomes of gallbladder cancer patients: retrospective study from a high incidence region in India. South Asian J Cancer. 2023, 12:245-9. 10.1055\/s-0043-1761440","journal-title":"South Asian J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.356","article-title":"Histologic classification and grading enhances gallbladder cancer staging: A population-based prognostic score validated by the U.S. Extrahepatic Biliary Malignancy Consortium","volume":"35","author":"Tran T","year":"2017","unstructured":"Tran T, Ethun CG, Pawlik TM, et al.. Histologic classification and grading enhances gallbladder cancer staging: A population-based prognostic score validated by the U.S. Extrahepatic Biliary Malignancy Consortium. J Clin Oncol. 2017, 35:356. 10.1200\/JCO.2017.35.4_suppl.356","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485288-prognostic-significance-of-her-2neu-and-ki-67-expression-in-gallbladder-carcinoma-a-clinicopathological-study-across-resectable-and-advanced-stages","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:28:58Z","timestamp":1777361338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485288-prognostic-significance-of-her-2neu-and-ki-67-expression-in-gallbladder-carcinoma-a-clinicopathological-study-across-resectable-and-advanced-stages"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.107854","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}